Canada markets closed

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2400-0.0100 (-0.80%)
At close: 04:00PM EST
1.2300 -0.01 (-0.81%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.2500
Open1.2500
Bid1.2200 x 41800
Ask1.2400 x 36900
Day's Range1.2100 - 1.2600
52 Week Range1.0900 - 4.5300
Volume5,011,979
Avg. Volume5,216,960
Market Cap271.42M
Beta (5Y Monthly)3.71
PE Ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings DateFeb 23, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
  • Motley Fool

    1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell

    Ocugen (NASDAQ: OCGN) soared into the spotlight -- and its stock soared too -- when it entered the COVID-19 vaccine race two years ago. Or has Ocugen left center stage for good? Let's consider one reason to buy Ocugen in 2023 -- and two reasons to sell.

  • GlobeNewswire

    Ocugen Appoints Quan A. Vu as Chief Business Officer

    MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline. “Expanding Ocugen’s product portfolio and capabilities, in line w

  • GlobeNewswire

    Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

    MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Dr. Musunuri and members of Ocugen’s executive tea